FDA Approves CPR Devices Shown to Improve Survival of Cardiac Arrest

On March 9, the U.S. Food and Drug Administration (FDA) approved the ResQCPR System, which consists of two devices used together to perform cardiopulmonary resuscitation (CPR) on patients with cardiac arrest. The first device, the ResQPump Active Compression Decompression CPR Device, uses a double-grip handle with a suction cup to attach to the patient’s chest, allowing the rescuer to apply pressure during compressions and lift for decompressions. The second device, the ResQPod 16.0 Impedance Threshold Device, attaches to a rescue mask to obstruct airflow into the chest during chest compressions. Together, the two devices may increase the amount of oxygenated blood circulating through the patient’s body during CPR.

The FDA announcement states that the agency “reviewed data supporting the approval of the ResQCPR System, including a randomized clinical trial that compared survival rates of 813 subjects who received standard CPR to 842 subjects who received CPR with the ResQCPR System. The clinical trial results showed that a larger number of subjects who received CPR with the ResQCPR System survived cardiac arrest.”

Clinical Topics: Arrhythmias and Clinical EP, Implantable Devices, SCD/Ventricular Arrhythmias

Keywords: Cardiopulmonary Resuscitation, Decompression, Electric Impedance, Heart Arrest, Survival Rate, United States Food and Drug Administration

< Back to Listings